Johnson & Johnson has presented clinical trial data linking short-term treatment with RNAi therapy JNJ-3989 to sustained reductions in markers of hepatitis B infection. The data drop comes as J&J runs 48-week phase 2b trials of the Arrowhead-partnered drug in the pursuit of a functional cure.
Investigators administered three doses of JNJ-3989 to participants in 56 days to evaluate whether giving the RNAi therapy in combination with an existing treatment can degrade viral RNA and inhibit DNA formation to reduce levels of HBsAg, the surface antigen of the hepatitis B virus. The study then tracked the subjects for 48 weeks after the administration of the final dose of JNJ-3989.
By the end of the follow-up, 15 of the 38 patients who initially responded to JNJ-3989 still had a -1.0 log10 IU/mL or greater reduction in HBsAg. The average 392-day reduction in HBsAg among the 15 sustained responders was around -2.0 log10 IU/mL.
强生的JNJ-3989采用RNAi suppresses hepatitis B，感觉前途如何？版上大神说一说
。
Johnson & Johnson has presented clinical trial data linking short-term
treatment with RNAi therapy JNJ-3989 to sustained reductions in markers of
hepatitis B infection. The data drop comes as J&J runs 48-week phase 2b
trials of the Arrowhead-partnered drug in the pursuit of a functional cure.
Investigators administered three doses of JNJ-3989 to participants in 56
days to evaluate whether giving the RNAi therapy in combination with an
existing treatment can degrade viral RNA and inhibit DNA formation to reduce levels of HBsAg, the surface antigen of the hepatitis B virus. The study
then tracked the subjects for 48 weeks after the administration of the final dose of JNJ-3989.
By the end of the follow-up, 15 of the 38 patients who initially responded
to JNJ-3989 still had a -1.0 log10 IU/mL or greater reduction in HBsAg. The average 392-day reduction in HBsAg among the 15 sustained responders was
around -2.0 log10 IU/mL.